Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868641 · ClinicalTrials.gov registry record · NA
The TAIL-PrEP Study
A NA study, sponsored by Columbia University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT06868641 is a NA study that is actively recruiting participants, run by Columbia University. The registered enrollment target is 30 participants.
The verdict
NCT06868641, a NA study, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of the TAIL-PrEP study is to understand how to support the safe discontinuation of injectable long-acting cabotegravir (cab-LA) and lenacapavir (LEN) while maximizing the public health impact of biomedical HIV prevention interventions. In Aim 1, the study will pilot test and assess the acceptability and feasibility of the TAIL-PrEP intervention: for participants discontinuing cab-LA, this will consist of monthly cabotegravir drug level monitoring to provide personalized HIV prevention coaching, for participants considering discontinuing cab-LA or LEN, this will consist of a one-time personalized HIV prevention coaching session. In Aim 2, the study will refine the TAIL-PrEP intervention and implementation strategy based on findings from the pilot study.
Interventions
- BEHAVIORAL TAIL-PrEP for patients discontinuing cab-LA
- BEHAVIORAL TAIL-PrEP for patients considering discontinuing cab-LA
- BEHAVIORAL TAIL-PrEP for patients considering discontinuing LEN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06868641
The ClinicalTrials.gov registry entry for NCT06868641 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TAIL-PrEP for patients discontinuing cab-LA is the first listed.
NCT06868641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06868641 about?
NCT06868641 is a clinical study titled "The TAIL-PrEP Study". The goal of the TAIL-PrEP study is to understand how to support the safe discontinuation of injectable long-acting cabotegravir (cab-LA) and lenacapavir (LEN) while maximizing the public health impact of biomedical HIV prevention interventions. In Aim 1, the study will pilot test and assess the acce...
What is the current status of trial NCT06868641?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-06. Estimated completion is 2027-03.
What interventions are being tested in trial NCT06868641?
The interventions under investigation include: TAIL-PrEP for patients discontinuing cab-LA (BEHAVIORAL), TAIL-PrEP for patients considering discontinuing cab-LA (BEHAVIORAL), TAIL-PrEP for patients considering discontinuing LEN (BEHAVIORAL).
Who is sponsoring clinical trial NCT06868641?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.